Clinical trials: Esomeprazole, completed
Chest Pain, Gastroesophageal Reflux
Chest Pain Pilot Study
The purpose of this study is to compare the efficacy of Nexium® with placebo in relief of acid related pain or discomfort in the chest.
- Trial name
- NCT00251901
- Testing
- Esomeprazole
- Where
- 80 sites in Canada, Denmark and 4 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Helicobacter Pylori
Keverprazan Combined With Amoxicillin for the Treatment of Helicobacter Pylori
The objective of this clinical trial is to determine whether the interventional behavioral drug Keverprazan in combined with amoxicillin, is effective in treating initial Helicobacter pylori infections in adults and to assess the…
- Trial name
- NCT06851468
- Testing
- Keverprazan, Esomeprazole, Amoxicillin
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Key Laboratory for Gastrointestinal Diseases of Gansu Province
Osteoporosis
The Effect of Protein on Calcium Absorption and Gastric Acid Production
We have established that dietary protein is an important regulator of intestinal calcium absorption in humans. However, we do not understand the mechanism by which dietary protein is affecting calcium absorption.
- Trial name
- NCT00719160
- Testing
- esomeprazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University
Healthy
YH4808 Postprandial PK/PD Study in Healthy Subjects
A clinical Study to evaluate the safety and pharmacokinetics/pharmacodynamics(PK/PD) of YH4808 after repeated Oral administration and Postprandial state in healthy volunteers
- Trial name
- NCT01761513
- Testing
- YH4808
- Where
- South Korea
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Arthritis, Cardiovascular Diseases
Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients
The aim of this study is to compare celecoxib plus a PPI (esomeprazole) versus naproxen plus a PPI (esomeprazole) in preventing recurrent ulcer bleeding in arthritis patients with a history of ulcer bleeding who require…
- Conditions
- Arthritis, Cardiovascular Diseases, Cerebrovascular Disorders
- Trial name
- NCT00153660
- Testing
- Celecoxib(drug), Naproxen(drug)
- Where
- China
- Volunteers
- 514 people
- Sponsor
- Chinese University of Hong Kong
Hiatal Hernia, Hiatal Hernia With Gastroesophageal Reflux Disease
Complications of Laparoscopic Hiatal Hernia Repair Complicated by Gastroesophageal Reflux Disease Using the ERAS Protocol
Nissen fundoplication with cruroraphy performed according to ERAS protocols in patients with HH complicated by GERD.
- Trial name
- hiatal hernia (NCT07138235)
- Testing
- laparoscopic hiatal hernia repair
- Volunteers
- 106 people
- Sponsor
- Osh State University
NSAID Induced Gastropathy
Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy
Primary objective: To determine the levels of malondialdehyde (MDA) and immunohistochemistry surrogate of inflammation in patients with NSAID-induced gastric mucosal injury treated with Rebamipide 3x a day vs Esomeprazole 40mg…
- Trial name
- NCT00641004
- Testing
- Rebamipide and Esomeprazole
- Where
- 4 sites in Philippines
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical, Inc., Philippines
Neoplasms, Breast
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
This study will characterize the effect of elevated gastric pH mediated by the proton-pump inhibitor, esomeprazole, on the relative bioavailability of lapatinib in subjects with metastatic ErbB2 positive breast cancer.
- Trial name
- NCT00849329
- Testing
- lapatinib, lapatinib plus esomeprazole
- Where
- 4 sites in United States, South Korea and 1 more
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
GERD
Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance
The implications of sleep as it relates to the physiology and pathogenesis of a number of diseases has until recently been ignored.
- Trial name
- NCT01079884
- Testing
- esomeprazole 40 mg
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- David A. Johnson, MD
Healthy
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po
This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to…
- Trial name
- NCT00206050
- Testing
- Esomeprazole, pantoprazole
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Helicobacter Pylori Infection
Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection
From the profiles of antibiotic susceptibility data following eradication therapy, tetracycline, amoxicillin and levofloxacin are all good candidates of antibiotics used in the rescue treatment.
- Trial name
- NCT03779087
- Testing
- 10d TL quadruple therapy, 10d AL quadruple therapy
- Where
- Taiwan
- Volunteers
- 112 people
- Sponsor
- Ping-I (William) Hsu, M.D.
Asthma, Lung Diseases
Study of Acid Reflux in Asthma
The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to…
- Conditions
- Asthma, Lung Diseases, Lung Diseases, Obstructive
- Trial name
- NCT00069823
- Testing
- Esomeprazole
- Where
- 20 sites in United States
- Volunteers
- 403 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Helicobacter Pylori Infection, Dyspepsia
Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication
The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter…
- Conditions
- Helicobacter Pylori Infection, Dyspepsia, Peptic Ulcer Disease, Helicobacter Pylori
- Trial name
- NCT07537634
- Testing
- vonoprazan-based triple therapy (VAL regimen), Esomeprazole-based triple therapy (EAL regimen)
- Where
- Bangladesh
- Volunteers
- 80 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Gastroesophageal Reflux Disease
Esomeprazole in PPI Failures - IMPROVE
The purpose of this study is to assess how PPI treated GERD patients with insufficient symptom control will benefit from a change in management by providing a more efficient acid secretion inhibition during 4 weeks, by evaluation…
- Trial name
- NCT00272701
- Testing
- Esomeprazole, Other PPI marketed in Sweden
- Where
- 42 sites in Sweden
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Healthy
A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood
The main objective of this trial is to investigate: the relative bioavailability of Avenciguat (BI 685509) TF2 (Reference, R) vs.
- Trial name
- NCT06193811
- Testing
- Avenciguat (BI 685509) (intended commercial formulation (iCF)), Avenciguat (BI 685509) (trial formulation 2 (TF2)), esomeprazole
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Valvular Heart Disease
The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass
This study evaluates the enhanced recovery after surgery (ERAS) concept over conventional postoperative care in patients with heart valve disease undergoing cardiac surgery with cardiopulmonary bypass.
- Trial name
- ERAS (NCT02479581)
- Testing
- ERAS group, Conventional control group
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Xiangya Hospital of Central South University
Healthy
A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood
The main objective of this trial is to investigate the effect of the proton pump inhibitor esomeprazole on the pharmacokinetics of BI 1819479 in plasma.
- Trial name
- NCT05467475
- Testing
- BI 1819479, Esomeprazole
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive…
- Trial name
- NCT00658775
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 83 sites in United States, Argentina and 12 more
- Volunteers
- 1,069 people
- Sponsor
- Eisai Inc.
Effect of Food, Pharmacokinetics
Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg
The purpose of the study is to investigate the effects of food, in comparison to fasting conditions, on the extent and rate of absorption of acetylsalicylic acid (ASA) and esomeprazole.
- Trial name
- NCT01163630
- Testing
- esomeprazole/ASA Fixed Dose Combination (FDC)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca